Investors

News & Publications

News Releases

News Releases

July 29, 2019
Arvinas Appoints Ronald Peck, M.D. as Chief Medical Officer
NEW HAVEN, Conn. , July 29, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today the appointment of Ronald Peck , M.D. to the newly created position of Chief Medical Officer (CMO). Dr.
June 20, 2019
Arvinas to Present at the BMO Prescriptions for Success Healthcare Conference
NEW HAVEN, Conn. , June 20, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that Ian Taylor , Ph.D., Chief Scientific Officer, will participate in a fireside chat at the BMO Prescriptions for
May 8, 2019
Arvinas Reports First Quarter Financial Results and Provides Corporate Update
Initiated Patient Dosing in the First Phase 1 Clinical Trial with a Targeted PROTAC® Protein Degrader, ARV-110 NEW HAVEN, Conn. , May 08, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrades disease-causing proteins,
Displaying 11 - 20 of 26